Poxel SA

7PO

Company Profile

  • Business description

    Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.

  • Contact

    259/261 Avenue Jean Jaures
    Immeuble le Sunway
    Lyon69007
    FRA

    T: +33 437372010

    https://www.poxel.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    6

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,828.7056.700.65%
CAC 407,738.4275.830.99%
DAX 4023,790.11116.820.49%
Dow JONES (US)44,484.4210.52-0.02%
FTSE 1008,774.6910.64-0.12%
HKSE24,221.41149.130.62%
NASDAQ20,393.13190.240.94%
Nikkei 22539,762.48223.85-0.56%
NZX 50 Index12,784.2949.760.39%
S&P 5006,227.4129.400.47%
S&P/ASX 2008,597.7056.600.66%
SSE Composite Index3,454.792.95-0.09%

Market Movers